Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CAR-T Abstract from Mayo Clinic (Vile group) using pela

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Jun 02, 2023 8:49am

117 Views

Post# 35476529

RE:RE:RE:RE:RE:RE:RE:CAR-T Abstract from Mayo Clinic (Vile group) using pela

Good Morning Capitalista,

I refer you to a press release dated April 14, 2022. In that release, it is stated - tumor cures greater than 80% of treated mice in each model.

So, it does seem that no OV boost in this current trial. Yet it seems they feel, had we boosted we expect that we would have attained 80% cures. If that is correct, it speaks to me of a high level of confidence and faith in The Pelareorep Boost.

As always, I am prepared to stand corrected.

<< Previous

Bullboard Posts

Next >>

Catch up with companies that got a Stanley Cup Playoffs boost